While Beam Therapeutics Inc has underperformed by -2.59%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BEAM rose by 1.91%, with highs and lows ranging from $49.50 to $16.95, whereas the simple moving average fell by -6.48% in the last 200 days.
On July 23, 2024, H.C. Wainwright started tracking Beam Therapeutics Inc (NASDAQ: BEAM) recommending Buy. A report published by JP Morgan on January 29, 2024, Upgraded its rating to ‘Overweight’ for BEAM. BofA Securities also Downgraded BEAM shares as ‘Neutral’, setting a target price of $35 on the company’s shares in a report dated December 15, 2023. Jefferies December 08, 2023d the rating to Hold on December 08, 2023, and set its price target from $75 to $30. Leerink Partners October 20, 2023d its ‘Outperform’ rating to ‘Market Perform’ for BEAM, as published in its report on October 20, 2023. Bernstein also rated the stock as ‘Mkt Perform’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Beam Therapeutics Inc (BEAM)
Further, the quarter-over-quarter decrease in sales is -41.48%, showing a negative trend in the upcoming months.
One of the most important indicators of Beam Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -17.17% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.81, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and BEAM is recording 1.13M average volume. On a monthly basis, the volatility of the stock is set at 5.30%, whereas on a weekly basis, it is put at 4.76%, with a gain of 9.49% over the past seven days. Furthermore, long-term investors anticipate a median target price of $50.36, showing growth from the present price of $25.62, which can serve as yet another indication of whether BEAM is worth investing in or should be passed over.
How Do You Analyze Beam Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 13.13%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 81.40% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BEAM shares are owned by institutional investors to the tune of 81.40% at present.
